Tubanur Çetinarslan, Muhammed Ali Mergen, Aylin Türel Ermertcan, Emel Bülbül Başkan, Serkan Yazıcı, İsa An, Gülhan Gürel, Esra Adışen, Abdullah Demirbaş, Recep Dursun, Bahadır Aslancan, Zeynep Topkarcı, Mustafa Esen, Zafer Türkoğlu, Dilek Canat, Selim Kandiş, Arzu Kılıç, İlgen Ertam, Elif Irmak Yazıcı, Ece Gökyayla, Neslihan Demirel Öğüt, Özge Sevil Karstarlı Bakay, Selami Aykut Temiz, Vefa Aslı Erdemir, Fatma Aslı Hapa, Ömer Aydın, Pelin Hızlı, Berna Solak, Melike Bütüner, Sema Aytekin, Hülya Albayrak, Munise Daye, Ümit Türsen, Ayşe Nur Sarıbaş Yıldırım, Beyhan Cengiz Özyurt
Purpose/Aim of the study: The efficacy of bimekizumab was shown in moderate to severe plaque psoriasis. The aim of this study was to investigate the early super responder (ESR) profile (at week 4) to bimekizumab.Materials and Methods: We performed a multicenter retrospective study in 20 Dermatology outpatient clinics in Turkey. Adult patients with moderate-to-severe psoriasis who were under bimekizumab for at least 12 weeks were enrolled.Results: A total of 341 adult patients were included. 136 had nail psoriasis (39.9%), 148 had psoriatic arthritis (PsA) (43.4%), 223 (65.4%) had at least one difficult-to-treat area involvement, 155 (45.5%) were bio-naïve, 110 (32.5%) had ≥ 2 biologics history. At week 4, PASI75 was achieved in 144 patients (49.8%), PASI90 was achieved in 88 patients (30.4%), PASI100 was achieved in 51 patients (17.6%). Family history (p = 0.041), palmoplantar involvement (p = 0.008), PsA (p = 0.097), and bio-experienced status (p = 0.060) were associated with lower odds of being an ESR, whereas each 1-point increase in baseline PASI was associated with significantly lower odds of ESR (p < 0.001). Gender, age, disease duration, history of conventional systemic treatment, and presence of any comorbidity were not significantly associated with the likelihood of being an ESR (all p > 0.05).Conclusion: Bimekizumab is the effective treatment in both bio-naïve and bio-experienced patients; however, it may have a more rapid onset of action in bionaive patients. Further studies are needed on the long-term efficacy and safety data of bimekizumab.